Growth in generics Dr. Reddy's operates with a broad portfolio including APIs, generics, branded generics, biosimilars and OTC, with recent launches such as Obeda and Bosutinib tablets. Opportunity: target expanded genericization collaborations, private label opportunities, and new market entry with cost-competitive formulations to capture price-sensitive segments in the US, India, and CIS markets.

Strategic partnerships Recent news highlights exclusive distribution of Takeda's Qdenga dengue vaccine in India and US-market cancer drug Bosutinib collaboration. Opportunity: pursue co-development or distribution deals for related vaccines, oncology generics, and specialty medicines, leveraging Dr. Reddy's regulatory and manufacturing footprint.

Obesity therapeutic push Dr. Reddy's is actively competing in India's growing obesity-drug market with lower-cost generic semaglutide products, alongside Novo Nordisk and other players. Opportunity: initiate BD conversations for regional obesity management portfolios, including supply of generics, related APIs, and supporting services for dosage forms and patient access solutions.

Supply-chain resilience API quality incidents impacted semaglutide supply in July 2026, signaling sensitivity in specialty APIs and manufacturing controls. Opportunity: propose end-to-end supply chain strengthening, API qualification services, alternative sourcing, and risk mitigation offerings to reduce stockouts for high-demand generics.

Digital & OTC expansion Hiveminds boosted Dr. Reddy’s digital presence and e-commerce engagement for OTC and nutrition brands; ongoing tech stack includes digital tools and customer-service platforms. Opportunity: offer e-commerce acceleration, digital marketing, and D2C enablement services, plus data-driven insights for better OTC portfolio performance and patient engagement.